See more : Studio Bank (STBK) Income Statement Analysis – Financial Results
Complete financial analysis of Fresh Tracks Therapeutics, Inc. (FRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresh Tracks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China PengFei Group Limited (3348.HK) Income Statement Analysis – Financial Results
- Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) Income Statement Analysis – Financial Results
- Adamera Minerals Corp. (ADZ.V) Income Statement Analysis – Financial Results
- Transpaco Limited (TPC.JO) Income Statement Analysis – Financial Results
- Jiangsu Changbao Steeltube Co.,Ltd (002478.SZ) Income Statement Analysis – Financial Results
Fresh Tracks Therapeutics, Inc. (FRTX)
About Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.01M | 6.94M | 404.00K | 1.82M | 7.92M | 1.62M | 13.82M | 14.53M | 20.95M | 15.22M | 7.72M | 17.52M | 30.02M | 8.71M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 7.62M | 10.70M | 5.90M | 7.80M | 6.70M | 6.30M | 5.50M | 6.00M | 3.60M | 2.40M | 1.80M |
| Cost of Revenue | 0.00 | 14.04M | 28.23M | 11.22M | 20.21M | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 0.00 | 10.27M | 11.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.00M | -900.00K | -900.00K | -600.00K | -500.00K | -500.00K | 5.70M | 4.00M | 3.00M | 2.20M |
| Gross Profit | 8.01M | -7.10M | -27.83M | -9.39M | -12.30M | 186.00K | 7.34M | 8.24M | 10.02M | 4.39M | -4.98M | 17.52M | 19.75M | -2.73M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 8.82M | 11.70M | 6.80M | 8.70M | 7.30M | 6.80M | 6.00M | 300.00K | -400.00K | -600.00K | -400.00K |
| Gross Profit Ratio | 100.00% | -102.26% | -6,887.87% | -515.59% | -155.32% | 11.47% | 53.12% | 56.71% | 47.84% | 28.87% | -64.52% | 100.00% | 65.80% | -31.28% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.75% | 109.35% | 115.25% | 111.54% | 108.96% | 107.94% | 109.09% | 5.00% | -11.11% | -25.00% | -22.22% |
| Research & Development | 3.18M | 14.04M | 28.23M | 11.22M | 20.21M | 12.33M | 14.39M | 10.36M | 11.06M | 11.47M | 14.56M | 17.34M | 17.98M | 19.69M | 23.45M | 25.53M | 22.93M | 18.51M | 17.77M | 31.18M | 26.78M | 26.37M | 22.07M | 18.51M | 15.30M | 12.10M | 11.90M | 11.30M | 9.00M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 0.00 | 8.80M | 7.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 13.06M | 0.00 | 0.00 | 10.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 9.60M | 8.80M | 17.82M | 19.77M | 22.84M | 22.64M | 19.88M | 8.51M | 6.92M | 8.06M | 6.52M | 5.27M | 4.40M | 3.60M | 3.70M | 3.20M | 2.90M | 2.60M | 2.00M | 1.40M | 1.10M | 800.00K |
| Other Expenses | 0.00 | 441.00K | 839.00K | 0.00 | 0.00 | -1.44M | -6.48M | -6.29M | -10.93M | -10.82M | -12.70M | -13.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 482.22K | 4.20M | 0.00 | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| Operating Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 27.57M | 28.49M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 24.98M | 20.70M | 16.60M | 16.50M | 15.10M | 12.40M | 11.40M | 2.40M | 1.80M | 1.70M | 1.40M |
| Cost & Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 37.84M | 39.93M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 23.78M | 19.70M | 15.70M | 15.60M | 14.50M | 11.90M | 10.90M | 8.10M | 5.80M | 4.70M | 3.60M |
| Interest Income | 0.00 | 9.00K | 69.00K | 63.00K | 1.94M | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 2.21M | 2.07M | 3.98M | 8.29M | 9.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.00K | 9.00K | 69.00K | 0.00 | 2.10M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 21.00K | 96.00K | 272.00K | 533.00K | 795.00K | 412.82K | 288.25K | 296.58K | 204.60K | 0.00 | 200.00K | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 100.00K | 100.00K |
| Depreciation & Amortization | 41.00K | 30.00K | 22.00K | 10.00K | 28.00K | 49.00K | 793.00K | 1.12M | 1.16M | 1.66M | 2.21M | 1.98M | 2.30M | 2.81M | 2.63M | 2.87M | 3.26M | 3.28M | 3.59M | 3.64M | 3.54M | 2.74M | 1.88M | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| EBITDA | -5.65M | -21.06M | -39.38M | -20.90M | -24.47M | -19.50M | -12.59M | -8.06M | -8.25M | -14.96M | -29.14M | -21.11M | -5.32M | -28.41M | -25.93M | -34.48M | -37.00M | -23.13M | -22.06M | -21.51M | -22.56M | -28.89M | -15.35M | -14.96M | -8.00M | -8.90M | -6.90M | -7.20M | -5.10M | -4.90M | -1.70M | -1.80M | -1.70M | -1.20M |
| EBITDA Ratio | -70.55% | -303.80% | -9,961.39% | -1,151.26% | -309.06% | -1,420.35% | -99.95% | -64.56% | -40.15% | -110.14% | -407.70% | -136.81% | -27.85% | -326.10% | -204.85% | -439.20% | -752.21% | -180.97% | -183.76% | -147.86% | -273.30% | -352.37% | -135.02% | -196.31% | -74.77% | -191.53% | -119.23% | -149.25% | -107.94% | -110.91% | -43.33% | -58.33% | -75.00% | -77.78% |
| Operating Income | -6.36M | -21.53M | -40.24M | -20.98M | -24.47M | -19.65M | -13.39M | -9.18M | -9.40M | -16.63M | -31.35M | -23.43M | -7.82M | -31.22M | -28.59M | -37.34M | -40.26M | -26.42M | -25.65M | -25.14M | -26.10M | -31.63M | -17.23M | -16.16M | -9.00M | -9.80M | -7.80M | -7.80M | -5.60M | -5.40M | -2.10M | -2.20M | -2.30M | -1.80M |
| Operating Income Ratio | -79.44% | -310.15% | -9,961.39% | -1,151.26% | -309.06% | -1,211.22% | -96.87% | -63.15% | -44.89% | -109.26% | -406.22% | -133.76% | -26.06% | -358.34% | -225.34% | -469.37% | -730.44% | -179.22% | -213.70% | -172.86% | -323.12% | -451.36% | -151.59% | -212.06% | -84.11% | -166.10% | -100.00% | -116.42% | -88.89% | -98.18% | -35.00% | -61.11% | -95.83% | -100.00% |
| Total Other Income/Expenses | 666.00K | 432.00K | 770.00K | 63.00K | 591.00K | 3.39M | 426.00K | 204.00K | 166.00K | 134.00K | 114.00K | 534.00K | 539.00K | 830.00K | 28.00K | 468.00K | 4.46M | 3.54M | 0.00 | 0.00 | -481.56K | -4.20M | 0.00 | 0.00 | 0.00 | 2.40M | 2.40M | 2.80M | 1.70M | 1.20M | 900.00K | 300.00K | 100.00K | 200.00K |
| Income Before Tax | -5.69M | -21.10M | -39.47M | -20.91M | -23.88M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.88M | -35.80M | -22.88M | 0.00 | 0.00 | -26.59M | -35.83M | 0.00 | 0.00 | 0.00 | -7.40M | -5.40M | -5.00M | -3.90M | -4.20M | -1.20M | -1.90M | -2.20M | -1.60M |
| Income Before Tax Ratio | -71.12% | -303.93% | -9,770.79% | -1,147.80% | -301.59% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.10% | -463.49% | -649.46% | -155.20% | 0.00% | 0.00% | -329.09% | -511.30% | 0.00% | 0.00% | 0.00% | -125.42% | -69.23% | -74.63% | -61.90% | -76.36% | -20.00% | -52.78% | -91.67% | -88.89% |
| Income Tax Expense | 0.00 | -441.00K | 47.00K | -10.00K | 2.07M | 4.48M | -1.22M | -1.32M | -166.00K | -1.80M | -2.33M | -2.52M | -2.84M | 0.00 | -28.00K | -447.00K | -4.37M | -3.27M | -1.29M | -1.41M | -1.65M | -3.70M | -7.99M | -7.64M | -2.10M | -2.30M | -2.20M | -2.70M | -1.60M | -1.00M | -700.00K | -200.00K | 0.00 | -100.00K |
| Net Income | -5.69M | -20.66M | -39.52M | -20.90M | -25.95M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.90M | -35.89M | -23.15M | -24.36M | -23.73M | -24.45M | -27.93M | -9.24M | -8.52M | -6.90M | -7.50M | -5.60M | -5.10M | -4.00M | -4.40M | -1.40M | -2.00M | -2.30M | -1.70M |
| Net Income Ratio | -71.12% | -297.58% | -9,782.43% | -1,147.26% | -327.71% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.11% | -463.75% | -651.20% | -157.04% | -202.92% | -163.17% | -302.65% | -398.62% | -81.29% | -111.77% | -64.49% | -127.12% | -71.79% | -76.12% | -63.49% | -80.00% | -23.33% | -55.56% | -95.83% | -94.44% |
| EPS | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.50K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| EPS Diluted | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.49K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| Weighted Avg Shares Out | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.02K | 4.92K | 4.88K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
| Weighted Avg Shares Out (Dil) | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.04K | 4.93K | 4.89K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
Fresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of Company
BOULDER, Colo. , Dec. 6, 2024 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) ("Fresh Tracks" or "the Company") announced today that a Scheduling Order has been issued by the Court of Chancery of the State of Delaware ("the...
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing...
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to...
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspended from trading on The Nasdaq Capital Market at the open of...
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th
Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension
Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 27, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Meeting adjourned to December 15, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in...
Source: https://incomestatements.info
Category: Stock Reports